Fifth ovarian cancer consensus conference: Individualized therapy and patient factors

Consensus conference; GCIG; Individualized therapy; Ovarian cancer; Recommendations; CA 125 antigen; Review; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Female; Humans; Precision Medicine

Abstract :

[en] This manuscript reports the consensus statements regarding the design and conduct of clinical trials in patients with newly diagnosed and recurrent epithelial ovarian cancer (EOC), following deliberation at the Fifth Ovarian Cancer Consensus Conference (OCCC), held in Tokyo in November 2015. Three important questions were identified for discussion prior to the meeting and achieved consensus during the meeting: (i) What are the most important factors to be evaluated prior to initial therapy? (ii) What are the most important factors to be evaluated specifically in recurrent disease? (iii) Are there specific considerations for special patient subpopulations? In addition, we report a list of important unmet needs compiled during the consensus process, which is intended to guide future research initiatives. © The Author 2017.

Disciplines :

Oncology

Author, co-author :

McGee, J.; CCTG, Kingston, Canada

Bookman, M.; GOG, Philadelphia, United States

Harter, P.; AGO, Wiesbaden, Germany

Marth, C.; AGO-AU, Innsbruck, Austria

McNeish, I.; MRC, NCRI, London, United Kingdom

Moore, K. N.; GOG, Philadelphia, United States

Poveda, A.; GEICO, Madrid, Spain

Hilpert, F.; AGO, Wiesbaden, Germany

Hasegawa, K.; GOTIC, Saitama, Japan

Bacon, M.; GCIG, Kingston, Canada

More authors (12 more)

Language :

English

Title :

Fifth ovarian cancer consensus conference: Individualized therapy and patient factors

Publication date :

2017

Journal title :

Annals of Oncology

ISSN :

0923-7534

eISSN :

1569-8041

Publisher :

Oxford University Press

Volume :

Issue :

Pages :

702-710

Peer reviewed :

Peer Reviewed verified by ORBi

Funders :

AstraZeneca
BMS - Bristol-Myers Squibb
Clovis Oncology
Eisai Co.
Roche
Pfizer
Pharma Mar.
TESARO
Zeria Pharmaceutical

Available on ORBi :

since 09 November 2020

Statistics

Number of views

70 (2 by ULiège)

Number of downloads

102 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Thigpen T, McAlpine J, Disaia P et al. First-Line Therapy in Ovarian Cancer Trials. Int J Gynecol Cancer 2011; 21(4): 756-762.
Prat J. Staging classication for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014; 124(1): 1-5.
Vergote I, Tropé CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363(10): 943-953.
Kehoe S, Hook J, Nankivell M et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386(9990): 249-257.
Winter WE, Maxwell GL, Tian C et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25(24): 3621-3627.
Winter WE, Maxwell GL, Tian C et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2008; 26(1): 83-89.
Du Bois A, Reuss A, Pujade-Lauraine E et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzin. Cancer 2009; 115(6): 1234-1244.
Hanker LC, Loibl S, Burchardi N et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/ platinum-based therapy. Ann Oncol 2012; 23(10): 2605-2612.
Chi DS, Ramirez PT, Teitcher JB et al. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual dis. J Clin Oncol 2007; 25(31): 4946-4951.
Sala E, Mannelli L, Yamamoto K et al. The value of postoperative/preadjuvant chemotherapy computed tomography in the management of patients with ovarian cancer. Int J Gynecol Cancer 2011; 21(2): 296-301.
Lakhman Y, Akin O, Sohn MJ et al. Early postoperative CT as a prognostic biomarker in patients with advanced ovarian, tubal, and primary peritoneal cancer deemed optimally debulked at primary cytoreductive surgery. AJR Am J Roentgenol 2012; 198(6): 1453-1459.
Lorusso D, Sarno I, Di Donato V et al. Is postoperative computed tomography evaluation a prognostic indicator in patients with optimally debulked advanced ovarian cancer? Oncology 2014; 87(5): 293-299.
Aletti GD, Dowdy SC, Gostout BS et al. Quality improvement in the surgical approach to advanced ovarian cancer: The Mayo Clinic Experience. J Am Coll Surg 2009; 208(4): 614-620.
Shih KK, Chi DS. Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol 2010; 21(2): 75-80.
Wimberger P, Wehling M, Lehmann N et al. Inuence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol 2010; 17(6): 1642-1648.
Sehouli J, Savvatis K, Braicu E-I et al. Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic singlecenter analysis. Int J Gynecol Cancer 2010; 20(8): 1331-1340.
Hamilton C. a, Miller A, Miller C et al. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol 2011; 122(3): 521-526.
Horowitz NS, Miller A, Rungruang B et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol 2015; 33(8): 937-943.
Aletti GD, Santillan A, Eisenhauer EL et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol 2007; 107(1): 99-106.
Aletti GD, Eisenhauer EL, Santillan A et al. Identication of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol 2011; 120(1): 23-28.
Zorn KK, Tian C, McGuire WP et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 2009; 115(5): 1028-1035.
Manganaro L, Michienzi S, Vinci V et al. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer. Oncol Rep 2013; 30(5): 2481-2487.
Granato T, Midulla C, Longo F et al. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumour Biol 2012; 33: 1335-1339.
Braicu EI, Chekerov R, Richter R et al. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with rst ovarian cancer relapse. Ann Surg Oncol 2014; 21(3): 955-962.
Schummer M, Drescher C, Forrest R et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol 2012; 125(1): 65-69.
Atkins CD. Neoadjuvant chemotherapy or primary surgery in advanced ovarian cancer. N Engl J Med 2010; 363(24): 2370-2372.
Du Bois A, Marth C, Psterer J et al. Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer. Int J Gynecol Cancer 2012; 22(2): 182-185.
Crawford SC, Vasey PA, Paul J et al. Does aggressive surgery only benet patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 2005; 23(34): 8802-8811.
Köbel M, Bak J, Bertelsen BI et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology 2014; 64(7): 1004-1013.
McCluggage WG, Lyness RW, Atkinson RJ et al. Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol 2002; 55: 27-31.
McCluggage WG. Morphological subtypes of ovarian carcinoma. Pathology 2011; 43(5): 420-432.
Vang R, Shih L. Ovarian low-grade and high grade serous carcinoma. Adv Anat Pathol 2010; 16(5): 267-282.
Vang R, Levine DA, Soslow RA et al. Molecular alterations of TP53 are a dening feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol 2016; 35(1): 48-55.
Ahmed AA, Etemadmoghadam D, Temple J et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010; 221(1): 49-56.
Singh N, Gilks CB, Wilkinson N, McCluggage WG. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology 2014; 65(2): 149-154.
Kurman RJ, Carcangiu ML, Herrington CSYR, WHO Classication of Tumours of Female Reproductive Organs. 4th edition. Geneva: WHO Press 2014.
McCluggage WG, Judge MJ, Clarke BA et al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Modern Pathol 2015; 28(8): 1101-1122.
Wu R, Hendrix-Lucas N, Kuick R et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/b- Catenin and PI3K/Pten signaling pathways. Cancer Cell 2007; 11(4): 321-333.
McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002; 55(5): 321-325.
Harter P, Johnson T, Berton-Rigaud D et al. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. Gynecol Oncol 2016; 140(3): 443-449.
Candido-dos-Reis FJ, Song H, Goode EL et al. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin Cancer Res 2015; 21(3): 652-657.
Hennessy BTJ, Timms KM, Carey MS et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benet from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010; 28(22): 3570-3576.
McNeish IA, Oza AM, Coleman RL et al. Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. J Clin Oncol 2015; 33(suppl): abstr 5508.
Pennington KP, Walsh T, Harrell MI et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014; 20(3): 764-775.
Bell D, Berchuck A, Birrer M et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474(7353): 609-615.
Abkevich V, Timms KM, Hennessy BT et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012; 107(10): 1776-1782.
Wang ZC, Birkbak NJ, Culhane AC et al. Proles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 2012; 18(15): 5806-5816.
Nakayama N, Nakayama K, Shamima Y et al. Gene amplication (CCNE)1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 2010; 116(11): 2621-2634.
Topp MD, Hartley L, Cook M et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol 2014; 8(3): 656-668.
Patch A-M, Christie EL, Etemadmoghadam D et al. Corrigendum: whole-genome characterization of chemoresistant ovarian cancer. Nature 2015; 527(7578): 398.
Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348(3): 203-213.
Psterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. J Clin Oncol 2004; 22(Suppl): abstr 5005.
Mahner S, Meier W, du Bois A et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinumsensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Eur J Cancer 2015; 51(3): 352-358.
Aghajanian C, Blank SV, Goff BA et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube. J Clin Oncol 2012; 30(17): 2039-2045.
Du Bois A, Kristensen G, Ray-Coquard I et al. Standard rst-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGOOVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2016; 17(1): 78-79.
Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365(26): 2473-2483.
Kim J-W, Mahner S, Wu L-Y et al. Pazopanib maintenance therapy in East Asian women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian study. Int J Gynecol Cancer 2015 November 19 [epub ahead of print].
Monk BJ, Poveda A, Vergote I et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014; 15(8): 799-808.
Perren TJ, Swart AM, Psterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365(26): 2484-2496.
Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28(15): 2512-2519.
Harter P, du Bois A, HahmannMet al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006; 13(12): 1702-1710.
Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000; 88(1): 144-153.
Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228-247.
Rustin GJS, Vergote I, Eisenhauer E et al. Denitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011; 21(2): 419-423.
Bookman MA, Gilks CB, Kohn EC et al. Better therapeutic trials in ovarian cancer. J Natl Cancer Inst 2014; 106(4): 1-8.
Ma BB, Hui EP, Mok TS. Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol 2010; 11(1): 75-84.
Fuh KC, Shin JY, Kapp DS et al. Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. Gynecol Oncol 2015; 136(3): 491-497.
Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2014; 58(2): 71-96.
Du Bois A, Floquet A, Kim J et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 2014; 32(30): 3374-3382.
Farley JH, Tian C, Rose GS et al. Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials. Cancer 2009; 115(18): 4210-4217.
Soo RA, Loh M, Mok TS et al. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials. J Thorac Oncol 2011; 6(6): 1030-1038.
Marsh S, Paul J, King CR et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish randomised trial in ovarian cancer. J Clin Oncol 2007; 25(29): 4528-4535.
Brenner H, Arndt V. Recent increase in cancer survival according to age: higher survival in all age groups, but widening age gradient. Cancer Causes Control 2004; 15(9): 903-910.
Micheli A, Coebergh JW, Mugno E et al. European health systems and cancer care. Ann Oncol 2003; 14(Suppl 5): v41-v60.
Gondos A, Holleczek B, Arndt V et al. Trends in population-based cancer survival in Germany: to what extent does progress reach older patients? Ann Oncol 2007; 18(7): 1253-1259.
Janda M, Youlden DR, Baade PD et al. Elderly patients with stage III or IV ovarian cancer: should they receive standard care? Int J Gynecol Cancer 2008; 18(5): 896-907.
Psterer J, Weber B, Reuss A et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in rst-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006; 98(15): 1036-1045.
Du Bois A, Lück HJ, Meier W et al. A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as rst-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95(17): 1320-1329.
Hilpert F, Wimberger P, du Bois A et al. Treatment of elderly ovarian cancer patients in the context of controleled clinical trials: a joint analysis of the AGO Germany experience. Onkologie 2012; 35(3): 76-81.
Wells KB. Treatment research at the crossroads: the scientic interface of clinical trials and effectiveness research. Am J Psychiatry 1999; 156(1): 5-10.
Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trial 2006; 1(1): e9.
Thrall MM, Goff BA, Symons RG et al. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol 2011; 118(3): 537-547.
Gerber DE, Laccetti AL, Xuan L et al. Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst 2014; 106(11): dju302.
Hamaker ME, Jonker JM, de Rooij SE et al. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol 2012; 13(10): 437-444.
González-Moreno S, Kusamura S, Baratti D, Deraco M. Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy. J Surg Oncol 2008; 98(4): 237-241.
Bohm S, Faruqi A, Said I et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol 2015; 33(22): 2457-2463.
Hamanishi J, Mandai M, Iwasaki M et al. Programmed cell death 1 ligand 1 and tumor-inltrating CD8(Thorn) T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007; 104(9): 3360-3365.